Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 3/20 | 0.57 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | CA5A | P35218 | 2/20 | 0.51 |
| ▸ | CA9 | Q16790 | 2/20 | 0.51 |
| ▸ | RXRA | P19793 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 5/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.44 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.44 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6472474 | 1.00 | AKR1C3 (0.57) | AKR1C3CA2CA5ACA9RXRA | |
| SCHEMBL6476140 | 0.93 | AKR1C3 (0.50) | AKR1C3CA2CA5ACA9RXRA | |
| SCHEMBL6476139 | 0.93 | AKR1C3 (0.50) | AKR1C3CA2CA5ACA9RXRA | |
| SCHEMBL6473692 | 0.93 | RXRA (0.58) | AKR1C3CA2CA5ACA9RXRA | |
| SCHEMBL6473686 | 0.93 | RXRA (0.58) | AKR1C3CA2CA5ACA9RXRA | |
| SCHEMBL6472794 | 0.92 | AKR1C3 (0.52) | AKR1C3CA2CA5ACA9RXRA | |
| SCHEMBL6472796 | 0.92 | AKR1C3 (0.52) | AKR1C3CA2CA5ACA9RXRA | |
| SCHEMBL6473731 | 0.92 | CA2 (0.51) | AKR1C3CA2CA5ACA9RXRA | |
| SCHEMBL6473733 | 0.92 | CA2 (0.51) | AKR1C3CA2CA5ACA9RXRA | |
| SCHEMBL6477087 | 0.92 | KDM4E (0.56) | AKR1C3RXRAKDM4ELMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6924388-B2 | Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-08-02 | — | — | US | claimed |
| EP-0947496-B1 | Bicyclic aromatic compounds and their use in human and veterinary medicine as well as in cosmetology | GALDERMA RES & DEV (FR) | 2002-10-09 | — | — | EP | claimed |
| US-6924388-B2 | Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-08-02 | — | — | US | disclosed |
| US-20040092594-A1 | Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2004-05-13 | — | — | US | disclosed |
| US-6632963-B1 | Are useful for the treatment of a wide variety of disease states, whether human or veterinary, for example dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders, as well as for the treatment of | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2003-10-14 | — | — | US | disclosed |
| EP-0947496-B1 | Bicyclic aromatic compounds and their use in human and veterinary medicine as well as in cosmetology | GALDERMA RES & DEV (FR) | 2002-10-09 | — | — | EP | disclosed |
| EP-0947496-A1 | Bicyclic aromatic compounds and their use in human and veterinary medicine as well as in cosmetology | Galderma Research & Development, S.N.C. (FR) | 1999-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092594-A1 | Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof | AHR, TYR, MC1R | AKR1C3 225/4885CA2 2147/4885CA5A 469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.